Recent Advancement in Topical Nanocarriers for the Treatment of Psoriasis

Overview

Journal AAPS PharmSciTech

Publisher Springer

Specialty Pharmacology

Date 2021 May 27

PMID 34041632

Citations 10

Authors

Prativa Biswasroy

Deepak Pradhan

Biswakanth Kar

Goutam Ghosh

Goutam Rath

Affiliations

Soon will be listed here.

Abstract

Psoriasis is a life-threatening autoimmune inflammatory skin disease, triggered by T lymphocyte. Recently, the drugs most commonly used for the treatment of psoriasis include methotrexate (MTX), cyclosporine (CsA), acitretin, dexamethasone, and salicylic acid. However, conventional formulations due to poor absorptive capacity, inconsistent drug release characteristics, poor capability of selective targeting, poor retention of drug molecules in target tissue, and unintended skin reactions restrict the clinical efficacy of drugs. Advances in topical nanocarriers allow the development of prominent drug delivery platforms can be employed to address the critical issues associated with conventional formulations. Advances in nanocarriers design, nano-dimensional configuration, and surface functionalization allow formulation scientists to develop formulations for a more effective treatment of psoriasis. Moreover, interventions in the size distribution, shape, agglomeration/aggregation potential, and surface chemistry are the significant aspects need to be critically evaluated for better therapeutic results. This review attempted to explore the opportunities and challenges of current revelations in the nano carrier-based topical drug delivery approach used for the treatment of psoriasis.

Citing Articles

Eugenol-Loaded Lipid Nanoparticles-Derived Hydrogels Ameliorate Psoriasis-like Skin Lesions by Lowering Oxidative Stress and Modulating Inflammation.

Keshari R, Tharmatt A, Pillai M, Chitkara D, Tayalia P, Banerjee R ACS Pharmacol Transl Sci. 2024; 7(11):3592-3606.

PMID: 39539275 PMC: 11555504. DOI: 10.1021/acsptsci.4c00493.

Clinical features and effects of cyclosporine in the treatment of psoriasis: a systemic review and meta-analysis.

Li Z, Pei B, Lei T, Yao M, Niu Y, Zhou P Arch Dermatol Res. 2024; 316(10):705.

PMID: 39460805 DOI: 10.1007/s00403-024-03425-y.

Intradermal Injection of a Thermoresponsive Polymeric Dexamethasone Prodrug (ProGel-Dex) Ameliorate Dermatitis in an Imiquimod (IMQ)-Induced Psoriasis-like Mouse Model.

Jiang H, Fu X, Zhao G, Du X, Georgesen C, Thiele G Mol Pharm. 2024; 21(10):4995-5004.

PMID: 39224912 PMC: 11687287. DOI: 10.1021/acs.molpharmaceut.4c00360.

Recent Advancements and Trends of Topical Drug Delivery Systems in Psoriasis: A Review and Bibliometric Analysis.

An P, Zhao Q, Hao S, Wang X, Tian J, Ma Z Int J Nanomedicine. 2024; 19:7631-7671.

PMID: 39099792 PMC: 11296365. DOI: 10.2147/IJN.S461514.

Nano transdermal system combining mitochondria-targeting cerium oxide nanoparticles with all-trans retinoic acid for psoriasis.

Wang W, Xu X, Song Y, Lan L, Wang J, Xu X Asian J Pharm Sci. 2023; 18(5):100846.

PMID: 37881797 PMC: 10594570. DOI: 10.1016/j.ajps.2023.100846.

References

Meng R, DeLaria G, Goldin M . Transjugular forceps retrieval of catheter embolus. Ann Thorac Surg. 1980; 29(6):575-7. DOI: 10.1016/s0003-4975(10)61711-0. View

Tripathi P, Gorain B, Choudhury H, Srivastava A, Kesharwani P . Dendrimer entrapped microsponge gel of dithranol for effective topical treatment. Heliyon. 2019; 5(3):e01343. PMC: 6431737. DOI: 10.1016/j.heliyon.2019.e01343. View

Walunj M, Doppalapudi S, Bulbake U, Khan W . Preparation, characterization, and evaluation of cyclosporine cationic liposomes for the treatment of psoriasis. J Liposome Res. 2019; 30(1):68-79. DOI: 10.1080/08982104.2019.1593449. View

VYHNALEK J, Wiedermann J, Vyhnalkova Z . [The transumbilical approach in the cardiologic diagnosis of newborn infants - pros and cons]. Cesk Pediatr. 1981; 36(9):533-5. View

Knudsen N, Ronholt S, Salte R, Jorgensen L, Thormann T, Basse L . Calcipotriol delivery into the skin with PEGylated liposomes. Eur J Pharm Biopharm. 2012; 81(3):532-9. DOI: 10.1016/j.ejpb.2012.04.005. View

Bahramizadeh M, Bahramizadeh M, Kiafar B, Jafarian A, Nikpoor A, Hatamipour M . Development, characterization and evaluation of topical methotrexate-entrapped deformable liposome on imiquimod-induced psoriasis in a mouse model. Int J Pharm. 2019; 569:118623. DOI: 10.1016/j.ijpharm.2019.118623. View

Srisuk P, Thongnopnua P, Raktanonchai U, Kanokpanont S . Physico-chemical characteristics of methotrexate-entrapped oleic acid-containing deformable liposomes for in vitro transepidermal delivery targeting psoriasis treatment. Int J Pharm. 2012; 427(2):426-34. DOI: 10.1016/j.ijpharm.2012.01.045. View

Bryant R, Olley J, Tyers M . Involvement of the median raphe nucleus in antinociception induced by morphine, buprenorphine and tilidine in the rat. Br J Pharmacol. 1982; 77(4):615-24. PMC: 2044677. DOI: 10.1111/j.1476-5381.1982.tb09339.x. View

Abu Hashim I, Abo El-Magd N, El-Sheakh A, Hamed M, Abd El-Gawad A . Pivotal role of Acitretin nanovesicular gel for effective treatment of psoriasis: ex vivo-in vivo evaluation study. Int J Nanomedicine. 2018; 13:1059-1079. PMC: 5824759. DOI: 10.2147/IJN.S156412. View

10.

Abdelbary A, AbouGhaly M . Design and optimization of topical methotrexate loaded niosomes for enhanced management of psoriasis: application of Box-Behnken design, in-vitro evaluation and in-vivo skin deposition study. Int J Pharm. 2015; 485(1-2):235-43. DOI: 10.1016/j.ijpharm.2015.03.020. View

11.

Kassem A, Abd El-Alim S, Hasanein Asfour M . Enhancement of 8-methoxypsoralen topical delivery via nanosized niosomal vesicles: Formulation development, in vitro and in vivo evaluation of skin deposition. Int J Pharm. 2016; 517(1-2):256-268. DOI: 10.1016/j.ijpharm.2016.12.018. View

12.

Coven T, Walters I, Cardinale I, Krueger J . PUVA-induced lymphocyte apoptosis: mechanism of action in psoriasis. Photodermatol Photoimmunol Photomed. 1999; 15(1):22-7. DOI: 10.1111/j.1600-0781.1999.tb00048.x. View

13.

Agarwal R, Katare O, Vyas S . Preparation and in vitro evaluation of liposomal/niosomal delivery systems for antipsoriatic drug dithranol. Int J Pharm. 2001; 228(1-2):43-52. DOI: 10.1016/s0378-5173(01)00810-9. View

14.

Benigni M, Pescina S, Grimaudo M, Padula C, Santi P, Nicoli S . Development of microemulsions of suitable viscosity for cyclosporine skin delivery. Int J Pharm. 2018; 545(1-2):197-205. DOI: 10.1016/j.ijpharm.2018.04.049. View

15.

Gupta A, Brown M, Ellis C, Rocher L, Fisher G, Baadsgaard O . Cyclosporine in dermatology. J Am Acad Dermatol. 1989; 21(6):1245-56. DOI: 10.1016/s0190-9622(89)70339-x. View

16.

Muram D, Drouin P, Thompson F, Oxorn H . Pyometra. Can Med Assoc J. 1981; 125(6):589-92. PMC: 1862642. View

17.

Amarji B, Garg N, Singh B, Katare O . Microemulsions mediated effective delivery of methotrexate hydrogel: more than a tour de force in psoriasis therapeutics. J Drug Target. 2015; 24(2):147-60. DOI: 10.3109/1061186X.2015.1058804. View

18.

Patel H, Barot B, Parejiya P, Shelat P, Shukla A . Topical delivery of clobetasol propionate loaded microemulsion based gel for effective treatment of vitiligo: ex vivo permeation and skin irritation studies. Colloids Surf B Biointerfaces. 2012; 102:86-94. DOI: 10.1016/j.colsurfb.2012.08.011. View

19.

Ferreira M, Barreiros L, Segundo M, Torres T, Selores M, Costa Lima S . Topical co-delivery of methotrexate and etanercept using lipid nanoparticles: A targeted approach for psoriasis management. Colloids Surf B Biointerfaces. 2017; 159:23-29. DOI: 10.1016/j.colsurfb.2017.07.080. View

20.

Beloshapko A, Berezovskaia I, Lukianov A, Shkarenkov A . [System for automatic recording of the orienting response in rats]. Patol Fiziol Eksp Ter. 1981; (3):61-2. View